Drug Profile
Research programme: Ebola therapeutics - BioSavita
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator BioSavita
- Class Antibodies; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Ebola virus infections
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Ebola-virus-infections in USA
- 02 Aug 2016 Research programme: Ebola therapeutics - BioSavita is available for licensing as of 02 Aug 2016. http://biosavita.com/
- 02 Aug 2016 Early research in Ebola virus infections in USA (unspecified route)